argenx SE (ARGNF)

Market Cap	43.57B +16.7%
Revenue (ttm)	4.24B +88.4%
Net Income	1.29B +55.1%
EPS	19.57 +53.1%
Shares Out	n/a
PE Ratio	33.73
Forward PE	25.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40
Average Volume	30
Open	708.72
Previous Close	n/a
Day's Range	708.72 - 708.72
52-Week Range	532.40 - 872.27
Beta	-0.18
RSI	47.83
Earnings Date	May 7, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,863
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARGNF

Financial Performance

In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.